The NTAA prognostic model redefines outcomes for BCLC stage B hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Analyzing over 2,500 patients, it identified tumor size, number, alpha-fetoprotein levels, and albumin-bilirubin grade as key survival predictors. Dividing patients into low, intermediate, and high-risk groups revealed median survival rates of 68.1, 35.7, and 15.4 months, respectively. The model outperforms traditional criteria, enhancing clinical decision-making and personalizing treatment strategies.
Journal Article by Chen S, Shen L (…) Fan W et 17 al. in Int J Surg
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.